
Big congrats to Singderm®, a whole new generation dermal filler developed by Singclean Medical, getting CE mark today!
Singderm® project begun in 2013. In 2015, Singclean has built a controllable and adjustable cross-linking technology platform and realized the unique SingLink® patented cross-linking technology through international cooperation and partnerships. In 2018, Singderm® has passed 12-month clinical verification in three tier 3 hospitals in China with high stability, safety and effectiveness while obtaining CFDA certification early this year.
What's Singderm®?
Singderm® is made of cross-linked, non-animal hyaluronic acid obtained by bio-fermentation technology. It is a 24 mg/ml hyaluronic acid-based dermal filler which is mono-phasic and contains 0.3% lidocaine to reduce injection pain.
Intended Use
Singderm® dermal filler is indicated for injection into the mid to deep dermis or subcutaneous for smoothing moderate to severe facial wrinkles and folds, restoring age-related volume loss, as well as improving facial contours, which is more similar to Juvederm_Ultra_Plus_XC.
Specifications
1ml, 2ml, 10ml with 27G/26G needle
How Long Does Singderm® Last?
Typically, the effects can last at least 12 month, but the longevity can also be affected by various factors, like where the filler is used, how much is injected and the individual's metabolic rate.
Before and After Photos
![F{(4@K2W`{PJJ04]3EQKPR7](/ueditor/php/upload/image/20201102/1604294715868768.png)
Recommended Areas for Singderm® Injection
![HJKCMI@3F]_79PKZMKRQIVT](/ueditor/php/upload/image/20201102/1604294722753744.png)
Clinical Data
![$}${OM@Y]6[@W]0G[C]VXWB](/ueditor/php/upload/image/20201102/1604294730114606.png)
Why choose Singderm®?
1. Safe and Reliable
Singderm®, being animal-origin free, is derived from Streptococcus fermentation; and is terminally sterilized by the moist heat method, the product's sterility assurance level is increased from one thousandth to one millionth, product safety is significantly improved; BD HylokTM professional hyaluronic acid syringe with safe and robust needle connection is adopted. Multiple ways ensure the safety of the product, so far no adverse event feedback has been received.
2. Good Biocompatibility
Singderm® is similar to the body's own naturally produced hyaluronic acid with stable structure and high tissue affinity. The osmotic pressure and PH value are close to the human body, greatly reducing the probability of redness and swelling.
3. Soft and Natural
Singderm® is a mono-phase hyaluronic acid, which is a smooth and homogeneous gel, soft in texture without foreign body sensation, creating a more natural look and a major lifting effect.
4. High Viscoelasticity
High viscosity will not be easy for dermal filler to shift and deform; high elasticity can offer strong supporting force with strong ability to resist deformation caused by external force. The perfect combination of viscosity and elasticity can effectively improve uneven skin tone, enhance face shape and bring perfect and natural facelifts.
5. Long-Lasting effect
Stable crosslinking technology and high content of HA play a decisive role in the long-Lasting effect of dermal fillers. According to multi-center clinical verifications, the 6-month and 12-month effectiveness rate of Singderm® reaches 94.0% and 92.7% respectively while currently the highest 12-month effectiveness rate of the internationally well-known dermal filler is 83%.
6. Pleasant and Painless Experience
Singderm® contains 0.3% lidocaine, effectively reducing the pain caused by injection and giving patients better experience of slight pain or even no pain during the injection.
The Market Size of Dermal Filler
It's no doubt that the demand for injectable fillers is on the rise.
According to Grand View Research, the Europe hyaluronic acid based dermal fillers market size was estimated at USD 979.7 million in 2019 and is expected to grow at a compound annual growth rate of 7.6% from 2019 to 2026 to reach USD 1.4 billion by 2026 while single-phase products segment accounted for the largest Europe hyaluronic acid based dermal fillers market share, around 58% share in the market in 2019.
So don’t hesitate, take the chance, get ready to be surprised with our epoch-making Singderm® and work with us to create a successful business partnership!
-
singclean | 2020-11-02
Singclean’s Medical Sodium Hyaluronate Gel for Bone Joint Gained EU MDR CE Certification, Ranking Among First 3 Globally! 协合医疗骨科医用透明质酸钠凝胶成功斩获欧盟MDR CE认证!跻身全球前三!This achievement sets multiple industry records: it is the first MDR CE certificate for hyaluronic acid-based orthopedic products ever issued by DNV worldwide. Singclean Medical has become the first Chinese company to obtain such certification in this category and has successfully ranked among the first 3 companies globally to secure a viscosupplementation MDR CE certificate. This accomplishment underscores Singclean Medical's technological expertise and international competitiveness in the field of orthopedic biomaterials and hyaluronic acid applications. 此次认证创造了多项行业纪录:这是DNV在全球范围内签发的首张透明质酸骨科类MDR CE证书;协合医疗为中国首家获此证书的企业,更成功跻身全球前三。这一成绩,充分彰显了协合医疗在骨科生物医用材料及透明质酸领域的技术积累与国际竞争力。 -
singclean | 2020-11-02
Singclean Medical’s 2nd International Aesthetic Medicine Leadership Summit Concludes Successfully in Shanghai Shanghai, August 27, 2026 – The 2nd International Aesthetic Medicine Leadership Summit, hosted by Singclean Medical, was held at W Shanghai – The Bund, within the IMCAS China Congress venue. Under the theme “Global Vision, Opening a New Chapter,” the summit served as a cross‑border, multi‑disciplinary platform for professional exchange, gathering an impressive lineup of leading physicians and global partners. -
singclean | 2020-11-02
Singclean Medical to Showcase Innovative Aesthetic and Medical Solutions at Dubai Derma 2026 and Medical Fair Asia 2026HANGZHOU, China – Hangzhou Singclean Medical Products Co., Ltd., a leading innovator in absorbable biomaterials and medical aesthetic solutions, has announced its participation in two major international exhibitions in September 2026: Dubai Derma 2026 in the United Arab Emirates and Medical Fair Asia 2026 in Singapore.